Transcatheter tricuspid valve replacement is a new frontier in structural heart therapy — offering a catheter-based option for patients with severe tricuspid regurgitation who are too sick for open-heart surgery. Several systems are now in clinical trials and early commercial use.
The tricuspid valve sits between the right atrium and right ventricle, controlling blood flow to the lungs for oxygenation. For decades it was called "the forgotten valve" — tricuspid regurgitation was often undertreated because surgical repair carried high risk, particularly in the older, sicker patients who develop it most commonly.
Severe TR causes debilitating symptoms: massive fluid retention, swollen legs, an enlarged abdomen (ascites), liver congestion, kidney dysfunction, fatigue, and exercise intolerance. These patients often have limited treatment options — which is why transcatheter approaches are so important for this population.
TTVR involves delivering a prosthetic valve through the venous system (typically via the femoral vein or internal jugular vein) and implanting it in the tricuspid position. The procedure is performed under general anesthesia with echocardiographic and fluoroscopic guidance.
The tricuspid annulus is the largest valve annulus in the heart and is not calcified the way the aortic valve is — so anchoring a replacement valve is technically challenging. Device engineers have developed creative solutions including designs that anchor in the inferior vena cava, devices with self-expanding frames that conform to the annulus, and systems that capture the native leaflets.
Several TTVR systems are in clinical development, including the EVOQUE (Edwards Lifesciences), the LuX-Valve Plus (Jenscare), and others. The Evoque system received FDA approval in 2024 for severe symptomatic TR, making it the first transcatheter tricuspid valve replacement system available commercially in the US. Additional devices continue to advance through clinical trials.
Transcatheter tricuspid therapy is one of the most active areas of structural heart innovation. Between TEER (TriClip), TTVR, and other transcatheter approaches, patients with severe TR now have options that simply did not exist five years ago. Clinical trial enrollment is ongoing, and new data is presented regularly at major cardiology conferences.
TTVR is primarily intended for patients with severe symptomatic tricuspid regurgitation who are at high or prohibitive risk for open surgical repair or replacement. Many of these patients have multiple comorbidities, prior cardiac surgery, right ventricular dysfunction, or pacemaker/defibrillator leads crossing the valve. The heart team evaluates each patient's anatomy, symptoms, and overall health to determine the best approach.
Risks specific to TTVR include device migration or embolization, interference with pacemaker leads, right ventricular injury, residual or recurrent regurgitation, and the need for a permanent pacemaker. Because these are newer technologies, long-term durability data is still being collected. Patients should discuss the current evidence and individual risk-benefit balance with their structural heart team.